SREBF2 and breast cancer: However, this effect was inhibited by rapamycin (Fig. 6C, D), indicating that NUCB2/Nesfatin-1 promotes the synthesis of SREBP2 and HMGCR by activating the mTORC1 signaling pathway, thus promoting cholesterol synthesis in breast cancer cells.